193220-21-2

Basic information

• Product Name: 1-(2-BROMOETHOXY)-2-FLUOROBENZENE
• Synonyms: 1-(2-BROMOETHOXY)-2-FLUOROBENZENE;AKOS BBS-00006568;ASINEX-REAG BAS 11522233;TIMTEC-BB SBB011402;2-Fluorophenoxyethylbromide
• CAS NO: 193220-21-2
• Molecular Formula: C₈H₈BrFO
• Molecular Weight: 219.05
• Mol File: 193220-21-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 123 °C (16 mmHg)
• Flash Point: 125.2 °C
• Appearance: /
• Density: 1.486 g/cm³
• Vapor Pressure: 0.0343mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(2-BROMOETHOXY)-2-FLUOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMOETHOXY)-2-FLUOROBENZENE(193220-21-2)
• EPA Substance Registry System: 1-(2-BROMOETHOXY)-2-FLUOROBENZENE(193220-21-2)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-20/22
• Safety Statements: 37/39-26
• HazardClass: IRRITANT
• Hazardous Substances Data: 193220-21-2(Hazardous Substances Data)

Usage

Uses

1-(2-Bromo-ethoxy)-2-fluoro-benzene can be used to improve antipsychotic treatment.

InChI:InChI=1/C8H8BrFO/c9-5-6-11-8-4-2-1-3-7(8)10/h1-4H,5-6H2

Upstream product

• 367-12-4 2-fluorophenol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 350707-57-2 2-(2-(2-fluorophenoxy)ethyl)isoindoline-1,3-dione 
• 945906-95-6 4-[2-(2-fluoro-phenoxy)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 120351-90-8 2-(2-fluorophenoxy)ethanamine 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

Synthesis of new (arylcarbonyloxy)aminopropanol derivatives and the determination of their physico-chemical properties

Eight hydrochlorides of 3-{2-[(2/4-fluorophenoxy)-ethylamino]}-2- hydroxypropyl-4-alkoxybenzoates and four hydrochlorides of 3-tert-butylamino-2- hydroxypropyl-4-butoxybenzoates were prepared as potential antagonists of the β1-adrenergic receptor (beta-blockers). A multistep synthesis of these compounds is described as well as their detailed analytical characterization. The pharmacokinetic properties of these weak base compounds are significantly influenced by their acid-base dissociation constant, pK a. The knowledge of this value is crucial for new drug development. This paper is aimed at developing a methodology that utilizes pH-dependent 1H NMR spectroscopy for its routine analysis. The selected predicted physico-chemical parameters of the new (arylcarbonyloxy)aminopropanols (i.e., aryloxyaminopropanol derivatives) were compared with the model drugs esmolol and flestolol. [Figure not available: see fulltext.]